Clinical Trials

Nasopharyngeal Neoplasms

NCT06457503 2026-04-06

TRANSPARENT

Phase 4 Recruiting

100 enrolled

Nasopharyngeal Neoplasms

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

133 enrolled

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT02589938 2026-02-27

ACUPUNCTURE

Phase NA Completed

258 enrolled 16 charts

Phase 1/2 Active not recruiting

Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Radiation Injuries, Salivary Gland Neoplasms, Xerostomia

NCT05261750 2026-02-25

Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer

15 enrolled

Phase 1 Active not recruiting

Nasopharyngeal Neoplasms

NCT05239143 2026-02-09

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

180 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07332247 2026-02-04

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC

94 enrolled

Phase 3 Not yet recruiting

Nasopharyngeal Neoplasms

NCT07385079 2026-02-03

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

412 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Nasopharyngeal Neoplasms

NCT05983432 2026-01-29

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Phase 1 Recruiting

470 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 2 Completed

78 enrolled

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

418 enrolled

Nasopharyngeal Neoplasms

NCT05807880 2026-01-23

ALTER-HN005

59 enrolled

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Neoplasms

NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

61 enrolled 29 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Phase 1 Active not recruiting

126 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Intestinal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Nasopharyngeal Neoplasms, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Skin Neoplasms, Thymoma, Thymus Neoplasms, Colorectal Neoplasms, Adenocarcinoma, Clear Cell, Triple Negative Breast Neoplasms

NCT04004871 2025-12-11

Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2 Completed

60 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT07277764 2025-12-11

REDEFINE

23 enrolled

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06851663 2025-12-08

Trop2-targeted immunoPET Imaging of Solid Tumors

Phase 2/3 Recruiting

400 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT02253238 2025-11-06

Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients

Phase NA Active not recruiting

427 enrolled

GastrointestinalGynecologicHead & Neck

Dehydration, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

NCT03144661 2025-10-21

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Phase 1 Terminated

25 enrolled

Acrocephalosyndactylia, Esophageal Neoplasms, Carcinoma, Hepatocellular, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma

NCT04925544 2025-10-21

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

13 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT05305131 2025-09-23

Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

50 enrolled

Phase 2 Enrolling by invitation

Nasopharyngeal Neoplasms

NCT06688175 2025-08-07

IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma

32 enrolled

Nasopharyngeal Neoplasms

NCT05581550 2025-07-20

Somatostatin Receptor Imaging in NPC, EBV Related Cancers

Phase NA Completed

15 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Nasopharyngeal Neoplasms

NCT05592626 2025-07-09

START-001

Phase 1/2 Recruiting

365 enrolled

Abdominal Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Genital Neoplasms, Female, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms, Urogenital Neoplasms, Vulvar Diseases, Vulvar Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Epstein-Barr Virus Infections, Papillomavirus Infections, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

208 enrolled

Phase NA Active not recruiting

Pathologic Complete Response, Nasopharyngeal Neoplasms

NCT07042711 2025-06-29

Impact of Vitamin D on Therapeutic Respons in NPC Chemoradiated Patients

300 enrolled

Nasopharyngeal Neoplasms

NCT06749899 2025-05-22

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Phase 3 Recruiting

580 enrolled

Nasopharyngeal Neoplasms

NCT06802835 2025-05-16

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

148 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT04875611 2025-04-24

NIVONASO-21

32 enrolled

Nasopharyngeal Neoplasms

NCT06682442 2025-04-20

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

Phase NA Recruiting

66 enrolled

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT04151264 2025-03-30

Influence of the "Hypotension Probability Index" on Intraoperative and Postoperative Hypotension in ENT- and OM-Surgery

Phase NA Completed

75 enrolled

GenitourinaryHead & Neck

Hypotension, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Otorhinolaryngologic Diseases, Acute Kidney Injury

NCT06892431 2025-03-25

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

150 enrolled

Nasopharyngeal Neoplasms, Recurrence

NCT03924986 2025-01-31

RATIONALE-309

Phase 3 Completed

263 enrolled 19 charts

Phase 3 Active not recruiting

Nasopharyngeal Neoplasms, Recurrence

NCT05587374 2025-01-23

GEMSTONE

490 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06349889 2025-01-15

Adebrelimab and Chemoradiotherapy in High-risk LANPC

50 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT03840421 2025-01-13

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

468 enrolled

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

NCT06414577 2024-12-30

Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

38 enrolled

Nasopharyngeal Neoplasms

NCT06733948 2024-12-13

ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients

50 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT02538510 2024-11-26

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

Phase 1/2 Completed

50 enrolled 13 charts

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Salivary Gland Neoplasms

NCT03813394 2024-11-22

2018/00947

48 enrolled

Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT03769467 2024-11-14

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Phase 1/2 Terminated

12 enrolled 8 charts